클로나제팜 사용의 현실적 문제들

키워드

참고문헌 (372)

1. Browne TR, "Clonazepam. A review of a new anticonvulsant drug", Arch Neurol, 33, pp.326~332 (1976)
2. "Chong Kun Dang’s epilepsy drug ‘Rivotril’ sold out…“Resumption of supply next month”"[URL]
3. "Klonopin tablets (clonazepam)"[URL]
4. Balon R, "Role of benzodiazepines in anxiety disorders", Adv Exp Med Biol, 1191, pp.367~388 (2020)
5. Spier SA, "Treatment of panic disorder and agoraphobia with clonazepam", J Clin Psychiatry, 47, pp.238~242 (1986)
6. Lechin F, "Pharmacomanometric studies of colonic motility as a guide to the chemotherapy of schizophrenia", J Clin Pharmacol, 20, pp.664~671 (1980)
7. Chouinard G, "A double-blind randomized clinical trial of rapid tranquilization with I.M. clonazepam and I.M. haloperidol in agitated psychotic patients with manic symptoms", Can J Psychiatry, 38(Suppl 4), pp.S114~S121 (1993)[DOI]
8. Frykholm B, "Clonazepam--antipsychotic effect in a case of schizophrenia-like psychosis with epilepsy and in three cases of atypical psychosis", Acta Psychiatr Scand, 71, pp.539~542 (1985)
9. Freinhar JP, "Clonazepam : a novel therapeutic adjunct", Int J Psychiatry Med, 15, pp.321~328 (1985)
10. Kishimoto A, "Treatment of depression with clonazepam", Acta Psychiatr Scand, 77, pp.81~86 (1988)
11. Morishita S, "Clonazepam as a therapeutic adjunct to improve the management of psychiatric disorders", Psychiatry Clin Neurosci, 52, pp.75~78 (1998)
12. Chouinard G, "Issues in the clinical use of benzodiazepines: potency, withdrawal, and rebound", J Clin Psychiatry, 65(Suppl 5), pp.7~12 (2004)
13. Nardi AE, "Clonazepam in the treatment of psychiatric disorders : an update", Int Clin Psychopharmacol, 21, pp.131~142 (2006)
14. Morishita S, "Clonazepam as a therapeutic adjunct to improve the management of depression : a brief review", Hum Psychopharmacol, 24, pp.191~198 (2009)
15. Griffin CE 3rd, "Benzodiazepine pharmacology and central nervous system-mediated effects", Ochsner J, 13, pp.214~223 (2013)
16. Park WM, "Textbook of clinical neuropsychopharmacology", pp.154~168 (2019), Sigmapress
17. Vijay A, "Patterns and predictors of off-label prescription of psychiatric drugs", PLoS One, 13, pp.e0198363~ (2018)
18. "FDA requiring boxed warning updated to improve safe use of benzodiazepine drug class"[URL]
19. "FDA drug safety communication"[URL]
20. 심재환, "정신건강의학과 외래에서의 벤조디아제핀계 향정신성의약품 처방간격 관련요인 분석", 중독정신의학, 25(1), pp.9~17 (2021), 한국중독정신의학회
21. Jones BD, "Clonazepam in the treatment of recurrent symptoms of depression and anxiety in a patient with systemic lupus erythematosus", Am J Psychiatry, 142, pp.354~355 (1985)
22. Munjack DJ, "Clonazepam in the treatment of social phobia : a pilot study", J Clin Psychiatry, 51(Suppl), pp.35~40 (1990)
23. Gelernter CS, "Cognitive-behavioral and pharmacological treatments of social phobia. A controlled study", Arch Gen Psychiatry, 48, pp.938~945 (1991)
24. Davidson JR, "Treatment of social phobia with clonazepam and placebo", J Clin Psychopharmacol, 13, pp.423~428 (1993)
25. Adler LW, "Mixed bipolar disorder responsive to lithium and clonazepam", J Clin Psychiatry, 47, pp.49~50 (1986)
26. Kumar R, "Acute severe catatonia in a young woman with chronic schizophrenia responding to parenteral clonazepam", Aust N Z J Psychiatry, 35, pp.391~ (2001)
27. Winkler D, "Clonazepam in the long-term treatment of patients with unipolar depression, bipolar and schizoaffective disorder", Eur Neuropsychopharmacol, 13, pp.129~134 (2003)
28. Remington G, "Augmentation strategies in clozapine-resistant schizophrenia", CNS Drugs, 19, pp.843~872 (2005)
29. Post RM, "Acute and prophylactic effects of anticonvulsants in bipolar depression", Clin Neurosci Res, 2, pp.228~251 (2002)
30. Clothier JL, "Evaluation and treatment of catatonia", Am J Psychiatry, 146, pp.553~554 (1989)
31. Martényi F, "Clonazepam for the treatment of stupor in catatonic schizophrenia", Am J Psychiatry, 146, pp.1230~ (1989)
32. Kutcher S, "Successful clonazepam treatment of neuroleptic-induced akathisia in older adolescents and young adults: a double-blind, placebo-controlled study", J Clin Psychopharmacol, 9, pp.403~406 (1989)
33. Pujalte D, "A double-blind comparison of clonazepam and placebo in the treatment of neuroleptic-induced akathisia", Clin Neuropharmacol, 17, pp.236~242 (1994)
34. Saletu M, "Restless legs syndrome(RLS)and periodic limb movement disorder(PLMD) : acute placebo-controlled sleep laboratory studies with clonazepam", Eur Neuropsychopharmacol, 11, pp.153~161 (2001)
35. Mahowald MW, "Principles and practice of sleep medicine", pp.897~916 (2005), Elsevier
36. Shinno H, "Proposed dose equivalence between clonazepam and pramipexole in patients with restless legs syndrome", Prog Neuropsychopharmacol Biol Psychiatry, 34, pp.522~526 (2010)
37. Carlos K, "Benzodiazepines for restless legs syndrome", Cochrane Database Syst Rev, 3, pp.CD006939~ (2017)
38. Aurora RN, "Best practice guide for the treatment of REM sleep behavior disorder(RBD)", J Clin Sleep Med, 6, pp.85~95 (2010)
39. McCarter SJ, "Treatment outcomes in REM sleep behavior disorder", Sleep Med, 14, pp.237~242 (2013)
40. Li SX, "A prospective, naturalistic follow-up study of treatment outcomes with clonazepam in rapid eye movement sleep behavior disorder", Sleep Med, 21, pp.114~120 (2016)
41. Kimiagar I, "Rapid improvement of tardive dyskinesia with tetrabenazine, clonazepam and clozapine combined: a naturalistic long-term follow-up study", J Neurol, 259, pp.660~664 (2012)
42. Srour M, "Psychopharmacology of tic disorders", J Can Acad Child Adolesc Psychiatry, 17, pp.150~159 (2008)
43. Smith HS., "Current therapy in pain", pp.470~475 (2009), Elsevier
44. Jääskeläinen SK, "Is burning mouth syndrome a neuropathic pain condition?", Pain, 159, pp.610~613 (2018)
45. Yeon JA., "“Rivotril dilemma”...Psychiatric patients are struck by lightning", Medisobizanews, ~ (2011)
46. "ATC/DDD Index 2022"[URL]
47. Basit H, "Clonazepam" (2002), StatPearls
48. Preskorn SH, "A way of conceptualizing benzodiazepines to guide clinical use", J Psychiatr Pract, 21, pp.436~441 (2015)
49. Fennessy MR, "The effect of benzodiazepines on brain amines of the mouse", Arch Int Pharmacodyn Ther, 197, pp.37~44 (1972)
50. Jenner P, "Altered 5-HT metabolism with clonazepam, diazepam and diphenylhydantoin", J Pharm Pharmacol, 27, pp.707~710 (1975)
51. Morishita S, "Clonazepam in the treatment of prolonged depression", J Affect Disord, 53, pp.275~278 (1999)
52. Nardi AE, "Clonazepam for the treatment of panic disorder", Curr Drug Targets, 14, pp.353~364 (2013)
53. Sila-on W, "Influence of incorporation methods on partitioning behavior of lipophilic drugs into various phases of a parenteral lipid emulsion", AAPS PharmSciTech, 9, pp.684~692 (2008)
54. Patsalos PN, "Antiepileptic drugs--best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies", Epilepsia, 49, pp.1239~1276 (2008)
55. Olivera M, "Effect of common NAT2 variant alleles in the acetylation of the major clonazepam metabolite, 7-aminoclonazepam", Drug Metab Lett, 1, pp.3~5 (2007)
56. de Leon J., "A practitioner’s guide to prescribing antiepileptics and mood stabilizers for adults with intellectual disabilities", pp.55~74 (2012), Springer
57. Sweetman SC, "The complete drug reference", pp.343~344 (2002), Pharmaceutical Press
58. Riss J, "Benzodiazepines in epilepsy : pharmacology and pharmacokinetics", Acta Neurol Scand, 118, pp.69~86 (2008)
59. Crevoisier C, "Comparative singledose pharmacokinetics of clonazepam following intravenous, intramuscular and oral administration to healthy volunteers", Eur Neurol, 49, pp.173~177 (2003)
60. Hiemke C, "Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology : update 2017", Pharmacopsychiatry, 51, pp.9~62 (2018)
61. Baruzzi A, "Plasma levels of di-no-propylacetate and clonazepam in epileptic patients", Int J Clin Pharmacol Biopharm, 15, pp.403~408 (1977)
62. Regenthal R, "Drug levels : therapeutic and toxic serum", plasma concentrations of common drugs, 1999, pp.15, 529~544
63. Labbate LA, "The relationship of alprazolam and clonazepam dose to steady-state concentration in plasma", J Clin Psychopharmacol, 14, pp.274~276 (1994)
64. Yukawa E, "Pharmacoepidemiologic investigation of a clonazepam-valproic acid interaction by mixed effect modeling using routine clinical pharmacokinetic data in Japanese patients", J Clin Pharm Ther, 28, pp.497~504 (2003)
65. "Medication guide. Clonazepam tablets, USP CIV"[URL]
66. Lai AA, "Time-course of interaction between carbamazepine and clonazepam in normal man", Clin Pharmacol Ther, 24, pp.316~323 (1978)
67. Yukawa E, "Pharmacoepidemiologic investigation of a clonazepam-carbamazepine interaction by mixed effect modeling using routine clinical pharmacokinetic data in Japanese patients", J Clin Psychopharmacol, 21, pp.588~593 (2001)
68. Greenblatt DJ, "Fluoxetine impairs clearance of alprazolam but not of clonazepam", Clin Pharmacol Ther, 52, pp.479~486 (1992)
69. de Leon J, "Pharmacokinetic drug interaction studies must consider pharmacological heterogeneity, use of repeated dosing, and translation into a message understandable to practicing clinicians", J Clin Psychopharmacol, 29, pp.201~205 (2009)
70. Spina E, "Clinically relevant pharmacokinetic drug interactions with second-generation antidepressants : an update", Clin Ther, 30, pp.1206~1227 (2008)
71. Jiang P, "Effect of clonazepam co-administered with clozapine on the serum clozapine and norclozapine concentration of patients with schizophrenia : a retrospective survey", Shanghai Arch Psychiatry, 28, pp.318~325 (2016)
72. Flanagan RJ, "Haematological toxicity of drugs used in psychiatry", Hum Psychopharmacol, 23(Suppl 1), pp.27~41 (2008)
73. Gerson SL, "Polypharmacy in fatal clozapine-associated agranulocytosis", Lancet, 338, pp.262~263 (1991)
74. Blier P, "Lithium and clozapine-induced neutropenia", agranulocytosis, 1998, pp.13, 137~140
75. Whiskey E, "Restarting clozapine after neutropenia : evaluating the possibilities and practicalities", CNS Drugs, 21, pp.25~35 (2007)
76. Stahl SM, "Prescriber’s guide: Stahl’s essential psychopharmacology", pp.173~178 (2021), Cambridge University Press
77. "Clonazepam"[URL]
78. Miller ME, "Clonazepam acetylation in fast and slow acetylators", Clin Pharmacol Ther, 30, pp.343~347 (1981)
79. Joshi KG FR, "Off-label prescribing : how to limit your liability", Curr Psychiatry, 19, pp.38~39 (2020)
80. Baldwin DS, "Off-label prescribing in psychiatric practice", Adv Psychiatr Treat, 13, pp.414~422 (2007)
81. Devulapalli KK, "An analysis of the high psychotropic off-label use in psychiatric disorders : the majority of psychiatric diagnoses have no approved drug", Asian J Psychiatr, 2, pp.29~36 (2009)
82. Tournier M, "Patterns of antidepressant use in Quebec children and adolescents : trends and predictors", Psychiatry Res, 179, pp.57~63 (2010)
83. Stahl SM, "Stahl’s essential psychopharmacology: neuroscientific basis and practical applications" (2013), Cambridge University Press
84. "FDA history"[URL]
85. Wittich CM, "Ten common questions(and their answers)about off-label drug use", Mayo Clin Proc, 87, pp.982~990 (2012)
86. Mawhinney J, "Position statement on off-label treatments" (2016), American Psychiatric Association
87. Frauger E, "Evidence of clonazepam abuse liability : results of the tools developed by the French Centers for Evaluation and Information on Pharmacodependence(CEIP)network", Fundam Clin Pharmacol, 25, pp.633~641 (2011)
88. Hallfors DD, "The dependence potential of short half-life benzodiazepines : a meta-analysis", Am J Public Health, 83, pp.1300~1304 (1993)
89. Pauly V, "Monitoring of benzodiazepine diversion using a multi-indicator approach", Int Clin Psychopharmacol, 26, pp.268~277 (2011)
90. Høiseth G, "Has previous abuse of flunitrazepam been replaced by clonazepam?", Eur Addict Res, 21, pp.217~221 (2015)
91. Taipale H, "Incidence of and characteristics associated with long-term benzodiazepine use in Finland", JAMA Netw Open, 3, pp.e2019029~ (2020)
92. Chouinard G, "New concepts in benzodiazepine therapy : rebound anxiety and new indications for the more potent benzodiazepines", Prog Neuropsychopharmacol Biol Psychiatry, 7, pp.669~673 (1983)
93. Fontaine R, "Antipanic effect of clonazepam", Am J Psychiatry, 141, pp.149~ (1984)
94. Schatzberg AF, "Essentials of clinical psychopharmacology", pp.539~569 (2006), American Psychiatric Publishing
95. Bandelow B, "World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders - first revision", World J Biol Psychiatry, 9, pp.248~312 (2008)
96. Dell’osso B, "Do benzodiazepines still deserve a major role in the treatment of psychiatric disorders? A critical reappraisal", Eur Psychiatry, 28, pp.7~20 (2013)
97. Bruce SE, "Are benzodiazepines still the medication of choice for patients with panic disorder with or without agoraphobia?", Am J Psychiatry, 160, pp.1432~1438 (2003)
98. Amrein R, "Panic disorder:neurobiological and treatment aspects", pp.237~253 (2016), Springer
99. Eppel AB, "Imipramine and clonazepam for panic disorder", Am J Psychiatry, 146, pp.283~284 (1989)
100. Goddard AW, "Early coadministration of clonazepam with sertraline for panic disorder", Arch Gen Psychiatry, 58, pp.681~686 (2001)
101. Pollack MH, "Combined paroxetine and clonazepam treatment strategies compared to paroxetine monotherapy for panic disorder", J Psychopharmacol, 17, pp.276~282 (2003)
102. Chouinard G, "The search for new off-label indications for antidepressant, antianxiety, antipsychotic and anticonvulsant drugs", J Psychiatry Neurosci, 31, pp.168~176 (2006)
103. Pollack MH, "Long-term management of panic disorder", J Clin Psychiatry, 51(Suppl), pp.11~13 (1990)[DOI]
104. Fuller MA., "The medical basis of psychiatry", pp.707~780 (2016), Springer
105. Nardi AE, "A three-year follow-up study of patients with the respiratory subtype of panic disorder after treatment with clonazepam", Psychiatry Res, 137, pp.61~70 (2005)
106. Nardi AE, "Psychopharmacotherapy of panic disorder : 8-week randomized trial with clonazepam and paroxetine", Braz J Med Biol Res, 44, pp.366~373 (2011)
107. Nardi AE, "A randomized, naturalistic, parallel-group study for the long-term treatment of panic disorder with clonazepam or paroxetine", J Clin Psychopharmacol, 32, pp.120~126 (2012)
108. Freire RC, "A 6-year posttreatment follow-up of panic disorder patients : treatment with clonazepam predicts lower recurrence than treatment with paroxetine", J Clin Psychopharmacol, 37, pp.429~434 (2017)
109. Worthington JJ 3rd, "Long-term experience with clonazepam in patients with a primary diagnosis of panic disorder", Psychopharmacol Bull, 34, pp.199~205 (1998)
110. "Clonazepam (Rx)"[URL]
111. Park WM, "Textbook of clinical neuropsychopharmacology", pp.338~346 (2019), Sigmapress
112. Dommisse CS, "Current concepts in clinical therapeutics:anxiety disorders, part 2", Clin Pharm, 6, pp.196~215 (1987)
113. Jefferson JW, "Social phobia: a pharmacologic treatment overview", J Clin Psychiatry, 56(Suppl 5), pp.18~24 (1995)
114. Versiani M, "Social phobia : long-term treatment outcome and prediction of response--a moclobemide study", Int Clin Psychopharmacol, 12, pp.239~254 (1997)
115. Versiani M, "A review of 19 double-blind placebo-controlled studies in social anxiety disorder(social phobia)", World J Biol Psychiatry, 1, pp.27~33 (2000)
116. Otto MW, "A comparison of the efficacy of clonazepam and cognitive-behavioral group therapy for the treatment of social phobia", J Anxiety Disord, 14, pp.345~358 (2000)
117. Hollander E, "Obsessive-compulsive disorder and obsessive-compulsive spectrum disorders : diagnostic and dimensional issues", CNS Spectr, 12(S3), pp.5~13 (2007)
118. Koran LM, "Practice guideline for the treatment of patients with obsessive-compulsive disorder", Am J Psychiatry, 164(7 Suppl), pp.5~53 (2007)
119. Hewlett WA, "Clonazepam treatment of obsessions and compulsions", J Clin Psychiatry, 51, pp.158~161 (1990)
120. Jenner P, "Mechanism of action of clonazepam in myoclonus in relation to effects on GABA and 5-HT", Adv Neurol, 43, pp.629~643 (1986)
121. Hewlett WA, "Clomipramine, clonazepam, and clonidine treatment of obsessive-compulsive disorder", J Clin Psychopharmacol, 12, pp.420~430 (1992)
122. Hollander E, "A double-blind, placebo-controlled trial of clonazepam in obsessive-compulsive disorder", World J Biol Psychiatry, 4, pp.30~34 (2003)
123. Crockett BA, "A double-blind combination study of clonazepam with sertraline in obsessive-compulsive disorder", Ann Clin Psychiatry, 16, pp.127~132 (2004)
124. Evelyn Stewart S, "Psychiatric neurotherapeutics", pp.23~50 (2016), Springer
125. Gelpin E, "Treatment of recent trauma survivors with benzodiazepines : a prospective study", J Clin Psychiatry, 57, pp.390~394 (1996)
126. Braun P, "Core symptoms of posttraumatic stress disorder unimproved by alprazolam treatment", J Clin Psychiatry, 51, pp.236~238 (1990)
127. Shalev AY, "Alprazolam reduces response to loud tones in panic disorder but not in posttraumatic stress disorder", Biol Psychiatry, 44, pp.64~68 (1998)
128. Shalev AY, "Auditory startle reflex in post-traumatic stress disorder patients treated with clonazepam", Isr J Psychiatry Relat Sci, 29, pp.1~6 (1992)
129. Albucher RC, "Psychopharmacological treatment in PTSD : a critical review", J Psychiatr Res, 36, pp.355~367 (2002)
130. Risse SC, "Severe withdrawal symptoms after discontinuation of alprazolam in eight patients with combat-induced posttraumatic stress disorder", J Clin Psychiatry, 51, pp.206~209 (1990)
131. Shader RI, "Use of benzodiazepines in anxiety disorders", N Engl J Med, 328, pp.1398~1405 (1993)
132. Farmer RF, "Behavioral interventions in cognitive behavior therapy: practical guidance for putting theory into action", pp.269~299 (2016), American Psychological Association
133. Peri T, "Embodied simulation in exposure-based therapies for posttraumatic stress disorder-a possible integration of cognitive behavioral theories, neuroscience, and psychoanalysis", Eur J Psychotraumatol, 6, pp.29301~ (2015)
134. Melani MS, "Absence of definitive scientific evidence that benzodiazepines could hinder the efficacy of exposure-based interventions in adults with anxiety or posttraumatic stress disorders : a systematic review of randomized clinical trials", Depress Anxiety, 37, pp.1231~1242 (2020)
135. Gould RA, "Cognitive-behavioral and pharmacological treatment for social phobia : a meta-analysis", Clin Psychol(New York), 4, pp.291~306 (1997)
136. Morissette SB, "Combining exposure and pharmacotherapy in the treatment of social anxiety disorder : a preliminary study of state dependent learning", J Psychopathol Behav Assess, 30, pp.211~219 (2008)
137. Allgulander C, "WCA recommendations for the long-term treatment of generalized anxiety disorder", CNS Spectr, 8(8 Suppl 1), pp.53~61 (2003)
138. Chessick CA, "Azapirones for generalized anxiety disorder", Cochrane Database Syst Rev, 2006, pp.CD006115~ (2006)
139. Seedat S, "Double-blind, placebo-controlled assessment of combined clonazepam with paroxetine compared with paroxetine monotherapy for generalized social anxiety disorder", J Clin Psychiatry, 65, pp.244~248 (2004)
140. Knijnik DZ, "A pilot study of clonazepam versus psychodynamic group therapy plus clonazepam in the treatment of generalized social anxiety disorder", Eur Psychiatry, 23, pp.567~574 (2008)
141. Simon NM, "An open-label study of levetiracetam for the treatment of social anxiety disorder", J Clin Psychiatry, 65, pp.1219~1222 (2004)
142. Barbui C, "Efficacy of antidepressants and benzodiazepines in minor depression : systematic review and meta-analysis", Br J Psychiatry, 198, pp.11~16 (2011)
143. Youssef NA, "Does acute treatment with sedatives", hypnotics for anxiety in depressed patients affect suicide risk? A literature review, 2008, pp.20, 157~169
144. American Psychiatric Association, "Practice guideline for the treatment of patients with major depressive disorder. 3rd ed", American Psychiatric Association, 152~ (2010)
145. Patten SB, "Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. I. Classification, burden and principles of management", J Affect Disord, 117(Suppl 1), pp.S5~S14 (2009)[DOI]
146. Svestka J, "Effectiveness of clonazepam in depressive disorders", Ceska Slov Psychiatr, 91, pp.199~207 (1995)[DOI]
147. Zetin M, "Clonazepam in bipolar affective disorder", Am J Psychiatry, 143, pp.1055~ (1986)
148. Lenox RH, "Adjunctive treatment of manic agitation with lorazepam versus haloperidol : a double-blind study", J Clin Psychiatry, 53, pp.47~52 (1992)
149. Sachs GS, "Use of clonazepam for bipolar affective disorder", J Clin Psychiatry, 51(Suppl), pp.31~34 (1990)[DOI]
150. Victor BS, "Use of clonazepam in mania and schizoaffective disorders", Am J Psychiatry, 141, pp.1111~1112 (1984)
151. Freinhar JP, "Use of clonazepam in two cases of acute mania", J Clin Psychiatry, 46, pp.29~30 (1985)
152. Santos AB, "More on clonazepam in manic agitation", J Clin Psychopharmacol, 7, pp.439~ (1987)
153. Sachs GS, "Adjunctive clonazepam for maintenance treatment of bipolar affective disorder", J Clin Psychopharmacol, 10, pp.42~47 (1990)
154. Edwards R, "Clonazepam in acute mania : a double blind trial", Aust N Z J Psychiatry, 25, pp.238~242 (1991)
155. Gouliaev G, "Treatment of manic episodes : zuclopenthixol and clonazepam versus lithium and clonazepam", Acta Psychiatr Scand, 93, pp.119~124 (1996)
156. Chadwick D, "Clinical, biochemical, and physiological features distinguishing myoclonus responsive to 5-hydroxytryptophan, tryptophan with a monoamine oxidase inhibitor, and clonazepam", Brain, 100, pp.455~487 (1977)
157. Browne TR, "Clonazepam", N Engl J Med, 299, pp.812~816 (1978)
158. Ballenger JC, "Carbamazepine in manic-depressive illness : a new treatment", Am J Psychiatry, 137, pp.782~790 (1980)
159. Bradwejn J, "Cholecystokinin-tetrapeptide induces panic attacks in patients with panic disorder", Can J Psychiatry, 35, pp.83~85 (1990)
160. Chouinard G, "Antimanic effects of clonazepam", Psychosomatics, 26(12 Suppl), pp.7~12 (1985)
161. Modell JG, "Inpatient clinical trial of lorazepam for the management of manic agitation", J Clin Psychopharmacol, 5, pp.109~113 (1985)
162. Lenox RH, "Acute treatment of manic agitation with lorazepam", Psychosomatics, 27(1 Suppl), pp.28~32 (1986)
163. Garza-Treviño ES, "Efficacy of combinations of intramuscular antipsychotics and sedative-hypnotics for control of psychotic agitation", Am J Psychiatry, 146, pp.1598~1601 (1989)
164. Salzman C, "Parenteral lorazepam versus parenteral haloperidol for the control of psychotic disruptive behavior", J Clin Psychiatry, 52, pp.177~180 (1991)
165. Battaglia J, "Haloperidol, lorazepam, or both for psychotic agitation? A multicenter, prospective, double-blind, emergency department study", Am J Emerg Med, 15, pp.335~340 (1997)
166. Foster S, "Efficacy of lorazepam and haloperidol for rapid tranquilization in a psychiatric emergency room setting", Int Clin Psychopharmacol, 12, pp.175~179 (1997)
167. Bieniek SA, "A doubleblind study of lorazepam versus the combination of haloperidol and lorazepam in managing agitation", Pharmacotherapy, 18, pp.57~62 (1998)
168. McAllister-Williams RH, "Rapid tranquillisation : time for a reappraisal of options for parenteral therapy", Br J Psychiatry, 180, pp.485~489 (2002)
169. Yildiz A, "Pharmacological management of agitation in emergency settings", Emerg Med J, 20, pp.339~346 (2003)
170. Curtin F, "Clonazepam and lorazepam in acute mania : a Bayesian meta-analysis", J Affect Disord, 78, pp.201~208 (2004)
171. Taylor MJ, "Association of genetic risk factors for psychiatric disorders and traits of these disorders in a Swedish population twin sample", JAMA Psychiatry, 76, pp.280~289 (2019)
172. Gelenberg AJ, "Lithium efficacy and adverse effects", J Clin Psychiatry, 49(Suppl), pp.8~11 (1988)
173. Post RM, "Psychiatry update:American Psychiatric Association annual review", pp.125~150 (1986), American Psychiatric Press
174. Kane JM, "The role of neuroleptics in manic-depressive illness", J Clin Psychiatry, 49(Suppl), pp.12~14 (1988)
175. Wegner JT, "Schizophrenics with tardive dyskinesia. Neuropsychological deficit and family psychopathology", Arch Gen Psychiatry, 42, pp.860~865 (1985)
176. Nasrallah HA, "Higher frequency of neuroleptic-induced dystonia in mania than in schizophrenia", Am J Psychiatry, 145, pp.1455~1456 (1988)
177. Chouinard G, "Clonazepam in acute and maintenance treatment of bipolar affective disorder", J Clin Psychiatry, 48(Suppl), pp.29~37 (1987)
178. Pollack MH, "Long-term outcome of panic disorder", Presented at the American Psychiatric Association 142nd Annual Meeting (1989)
179. Aronson TA, "Clonazepam treatment of five lithium-refractory patients with bipolar disorder", Am J Psychiatry, 146, pp.77~80 (1989)
180. Sachs GS, "Clonazepam vs. neuroleptics as adjuncts to lithium maintenance", Psychopharmacol Bull, 26, pp.137~143 (1990)
181. Karson CN, "Clonazepam treatment of chronic schizophrenia: negative results in a double-blind, placebo-controlled trial", Am J Psychiatry, 139, pp.1627~1628 (1982)
182. Cohen LS, "Clonazepam : new uses and potential problems", J Clin Psychiatry, 48(Suppl), pp.50~56 (1987)
183. Brunette MF, "Benzodiazepine use and abuse among patients with severe mental illness and co-occurring substance use disorders", Psychiatr Serv, 54, pp.1395~1401 (2003)
184. Clark RE, "Benzodiazepine prescription practices and substance abuse in persons with severe mental illness", J Clin Psychiatry, 65, pp.151~155 (2004)
185. Magliano L, "Prescription of psychotropic drugs to patients with schizophrenia : an Italian national survey", Eur J Clin Pharmacol, 60, pp.513~522 (2004)
186. Mauri MC, "Clinical outcome and olanzapine plasma levels in acute schizophrenia", Eur Psychiatry, 20, pp.55~60 (2005)
187. Haw C, "Benzodiazepines--a necessary evil? A survey of prescribing at a specialist UK psychiatric hospital", J Psychopharmacol, 21, pp.645~649 (2007)
188. Tor PC, "Adjunctive benzodiazepine treatment of hospitalized schizophrenia patients in Asia from 2001 to 2008", Int J Neuropsychopharmacol, 14, pp.735~745 (2011)
189. Sandyk R., "Successful treatment of neuroleptic-induced akathisia with baclofen and clonazepam. A case report", Eur Neurol, 24, pp.286~288 (1985)
190. Kutcher SP, "Clonazepam treatment of adolescents with neuroleptic-induced akathisia", Am J Psychiatry, 144, pp.823~824 (1987)
191. Horiguchi J, "Effect of clonazepam on neuroleptic-induced oculogyric crisis", Acta Psychiatr Scand, 80, pp.521~523 (1989)
192. Bodkin JA, "Emerging uses for high-potency benzodiazepines in psychotic disorders", J Clin Psychiatry, 51(Suppl), pp.41~46 (1990)[DOI]
193. Horiguchi J, "Usefulness of antiparkinsonian drugs during neuroleptic treatment and the effect of clonazepam on akathisia and parkinsonism occurred after antiparkinsonian drug withdrawal : a double-blind study", Jpn J Psychiatry Neurol, 46, pp.733~739 (1992)
194. Adler LA, "Paroxetine and akathisia", Biol Psychiatry, 37, pp.336~337 (1995)
195. Raines JM, "Clonazepam in the treatment of chronic schizophrenia", Am J Psychiatry, 144, pp.1510~ (1987)
196. Keats MM, "Antiaggressive effect of adjunctive clonazepam in schizophrenia associated with seizure disorder", J Clin Psychiatry, 49, pp.117~118 (1988)
197. Blake LM, "Clozapine and clonazepam in tardive dystonia", J Clin Psychopharmacol, 11, pp.268~269 (1991)
198. Kanofsky JF, "Relapse in a clozapine responder following lorazepam withdrawal", Am J Psychiatry, 150, pp.348~349 (1993)
199. Shapleske J, "Successful treatment of tardive dystonia with clozapine and clonazepam", Br J Psychiatry, 168, pp.516~518 (1996)
200. Wheeler AJ, "Treatment pathway and patterns of clozapine prescribing for schizophrenia in New Zealand", Ann Pharmacother, 42, pp.852~860 (2008)
201. Castle DJ, "Treatment–refractory schizophrenia: a clinical conundrum", pp.93~106 (2014), Springer
202. Bitter R, "Safety evaluation of the concomitant use of clozapine and benzodiazepines: a retrospective, cross-sectional chart review", J Psychiatr Pract, 14, pp.265~270 (2008)
203. Schutte-Rodin S, "Clinical guideline for the evaluation and management of chronic insomnia in adults", J Clin Sleep Med, 4, pp.487~504 (2008)
204. Gerlach M, "Psychiatric drugs in children and adolescents", pp.257~291 (2014), Springer
205. Contreras-González N, "Executive dysfunction in patients with chronic primary insomnia treated with clonazepam", Neurol Res, 37, pp.1047~1053 (2015)
206. Owens JA, "Pediatric insomnia", Pediatr Clin North Am, 58, pp.555~569 (2011)
207. Owens JA, "Update in pediatric sleep medicine", Curr Opin Pulm Med, 17, pp.425~430 (2011)
208. dos Santos VM, "Respiratory changes in Prader-Willi syndrome", Singapore Med J, 50, pp.107~ (2009)[DOI]
209. Schenck CH, "A polysomnographic and clinical report on sleep-related injury in 100 adult patients", Am J Psychiatry, 146, pp.1166~1173 (1989)
210. Schenck CH, "Long-term, nightly benzodiazepine treatment of injurious parasomnias and other disorders of disrupted nocturnal sleep in 170 adults", Am J Med, 100, pp.333~337 (1996)
211. Howell MJ, "Parasomnias : an updated review", Neurotherapeutics, 9, pp.753~775 (2012)
212. Attarian H, "Treatment options for disorders of arousal : a case series", Int J Neurosci, 123, pp.623~625 (2013)
213. Proserpio P, "Sleep disorders in children", pp.305~355 (2017), Springer
214. "Practice guidelines"[URL]
215. Chiaro G, "Treatment of sleep-related eating disorder", Curr Treat Options Neurol, 17, pp.361~ (2015)
216. Auger RR, "Sleep-related eating disorders", Psychiatry(Edgmont), 3, pp.64~70 (2006)
217. Howell MJ, "Treatment of nocturnal eating disorders", Curr Treat Options Neurol, 11, pp.333~339 (2009)
218. Silvestri R, "Sleep disorders in children", pp.389~404 (2017), Springer
219. Olson EJ, "Rapid eye movement sleep behaviour disorder: demographic, clinical and laboratory findings in 93cases", Brain, 123(Pt 2), pp.331~339 (2000)
220. Manni R, "Therapeutic symptomatic strategies in the parasomnias", Curr Treat Options Neurol, 20, pp.26~ (2018)
221. "REM sleep behavior disorder medication"[URL]
222. Schenck CH., "Polysomnographic, neurologic, psychiatric and clinical outcome report on 70 consecutive cases with REM sleep behavior disorder (RSBD): sustained clonazepam efficacy in 89.5% of 57treated patients", Cleve Clin J Med, 57, pp.9~23 (1990)
223. Lapierre O, "Polysomnographic features of REM sleep behavior disorder : development of a scoring method", Neurology, 42, pp.1371~1374 (1992)
224. Ferri R, "An observational clinical and video-polysomnographic study of the effects of clonazepam in REM sleep behavior disorder", Sleep Med, 14, pp.24~29 (2013)
225. Ferri R, "REM sleep EEG instability in REM sleep behavior disorder and clonazepam effects", Sleep, 40, pp.zsx080~ (2017)
226. Comella CL, "Treatment of restless legs syndrome", Neurotherapeutics, 11, pp.177~187 (2014)
227. Dokkedal-Silva V, "Clonazepam: indications, side effects, and potential for nonmedical use", Harv Rev Psychiatry, 27, pp.279~289 (2019)
228. Hanly P, "Hypnotics should never be used in patients with sleep apnea", J Psychosom Res, 37(Suppl 1), pp.59~65 (1993)
229. Kuźniar TJ, "Treatment of complex sleep apnea syndrome", Chest, 142, pp.1049~1057 (2012)
230. Palermo TM, "Rational pharmacotherapy for childhood sleep disturbances : characteristics of an ideal hypnotic", Curr Ther Res, 63, pp.B67~B79 (2002)[DOI]
231. Coleman DM, "Rating of the effectiveness of 26 psychiatric and seizure medications for autism spectrum disorder : results of a national survey", J Child Adolesc Psychopharmacol, 29, pp.107~123 (2019)
232. Arens R, "Periodic limb movement in sleep in children with Williams syndrome", J Pediatr, 133, pp.670~674 (1998)
233. Thirumalai SS, "Rapid eye movement sleep behavior disorder in children with autism", J Child Neurol, 17, pp.173~178 (2002)
234. Goraya JS, "Recurrent nocturnal tongue biting in a child with hereditary chin trembling", J Child Neurol, 21, pp.985~987 (2006)
235. Hollway JA, "Pharmacological treatment of sleep disturbance in developmental disabilities : a review of the literature", Res Dev Disabil, 32, pp.939~962 (2011)
236. Relia S, "Pharmacological approach to sleep disturbances in autism spectrum disorders with psychiatric comorbidities : a literature review", Med Sci(Basel), 6, pp.95~ (2018)
237. Han S, "Autistic-like behaviour in Scn1a+", -mice and rescue by enhanced GABA-mediated neurotransmission, 2012, pp.489, 385~390
238. Braat S, "The GABAA receptor as a therapeutic target for neurodevelopmental disorders", Neuron, 86, pp.1119~1130 (2015)
239. Olga Peñagarikano, "New Therapeutic Options for Autism Spectrum Disorder: Experimental Evidences", Experimental Neurobiology, 24(4), pp.301~311 (2015), 한국뇌신경과학회
240. Nakamura T, "The autism-related protein PX-RICS mediates GABAergic synaptic plasticity in hippocampal neurons and emotional learning in mice", EBioMedicine, 34, pp.189~200 (2018)
241. Dubovsky SL, "Kaplan and Sadock’s comprehensive textbook of psychiatry", pp.7644~7677 (2017), Wolters Kluwer
242. Bonnet U, "Comparison of two oral symptom-triggered pharmacological inpatient treatments of acute alcohol withdrawal: clomethiazole vs. clonazepam", Alcohol Alcohol, 46, pp.68~73 (2011)
243. Pauly V, "Detection of signals of abuse and dependence applying disproportionality analysis", Eur J Clin Pharmacol, 71, pp.229~236 (2015)
244. Baandrup L, "Antipsychotic polypharmacy and risk of death from natural causes in patients with schizophrenia : a population-based nested case-control study", J Clin Psychiatry, 71, pp.103~108 (2010)
245. Morigaki R, "Therapeutic perspective on tardive syndrome with special reference to deep brain stimulation", Front Psychiatry, 7, pp.207~ (2016)
246. Havaki-Kontaxaki BJ, "Treatment of severe neuroleptic-induced tardive torticollis", Ann Gen Hosp Psychiatry, 2, pp.9~ (2003)
247. Greene P, "Analysis of open-label trials in torsion dystonia using high dosages of anticholinergics and other drugs", Mov Disord, 3, pp.46~60 (1988)
248. Chuang C, "The natural history and treatment of acquired hemidystonia : report of 33 cases and review of the literature", J Neurol Neurosurg Psychiatry, 72, pp.59~67 (2002)
249. Pinninti NR, "Are second-generation antipsychotics useful in tardive dystonia?", Clin Neuropharmacol, 38, pp.183~197 (2015)
250. Thaker GK, "Clonazepam treatment of tardive dyskinesia : a practical GABAmimetic strategy", Am J Psychiatry, 147, pp.445~451 (1990)
251. Factor SA., "Therapy of movement disorders", pp.283~286 (2019), Humana Press
252. Lieberman JA, "The effects of clozapine on tardive dyskinesia", Br J Psychiatry, 158, pp.503~510 (1991)
253. Bassitt DP, "Clozapine efficacy in tardive dyskinesia in schizophrenic patients", Eur Arch Psychiatry Clin Neurosci, 248, pp.209~211 (1998)
254. Friedman JH, "Clozapine treatment of psychosis in patients with tardive dystonia : report of three cases", Mov Disord, 9, pp.321~324 (1994)
255. Trugman JM, "Treatment of severe axial tardive dystonia with clozapine : case report and hypothesis", Mov Disord, 9, pp.441~446 (1994)
256. Hazari N, "Clozapine and tardive movement disorders : a review", Asian J Psychiatr, 6, pp.439~451 (2013)
257. Pardis P, "Clozapine and tardive dyskinesia in patients with schizophrenia : a systematic review", J Psychopharmacol, 33, pp.1187~1198 (2019)
258. Bergman H, "Benzodiazepines for antipsychotic-induced tardive dyskinesia", Cochrane Database Syst Rev, 1, pp.CD000205~ (2018)
259. "Tardive dyskinesia: prevention, treatment, and prognosis"[URL]
260. Termsarasab P, "Medical treatment of dystonia", J Clin Mov Disord, 3, pp.19~ (2016)
261. Hong D, "Clonazepam improves the symptoms of two siblings with novel variants in the SYNJ1 gene", Parkinsonism Relat Disord, 62, pp.221~225 (2019)
262. "J Fr Ophtalmol", 1979, 95~102, French.
263. Yamaguchi N, "Psychopathology of schizophrenia", pp.295~314 (1985), Tokyo University Press
264. Slow EJ, "Oculogyric crises: a review of phenomenology, etiology, pathogenesis, and treatment", Mov Disord, 32, pp.193~202 (2017)
265. 정인원, "항정신병약물에 의한 안구운동발작과 발작성 지각변화 증후군", 대한조현병학회지, 21(1), pp.9~20 (2018), 대한조현병학회
266. Shorvon S, "Treatment of epilepsy", pp.829~854 (2009), Wiley-Blackwell
267. Camfield P, "The treatment of epilepsy", pp.421~430 (2009), Willey-Blackwell
268. Panayiotopoulos CP, "A clinical guide to epileptic syndromes and their treatment", pp.565~620 (2010), Springer
269. Naito H, "Clinical effects and plasma concentrations of long-term clonazepam monotherapy in previously untreated epileptics", Acta Neurol Scand, 76, pp.58~63 (1987)
270. Obeid T, "Clonazepam in juvenile myoclonic epilepsy", Epilepsia, 30, pp.603~606 (1989)
271. McEvoy GK, "American hospital formulatory service drug information", pp.1568~ (1996), American Society of Health System Pharmacist Inc
272. Hyde TM, "Seizures and schizophrenia", Schizophr Bull, 23, pp.611~622 (1997)
273. Rosebush PI, "Catatonia and its treatment", Schizophr Bull, 36, pp.239~242 (2010)
274. Fink M, "Neuroleptic malignant syndrome is malignant catatonia, warranting treatments efficacious for catatonia", Prog Neuropsychopharmacol Biol Psychiatry, 30, pp.1182~1183 (2006)[DOI]
275. Dhossche DM, "The medical basis of psychiatry", pp.517~535 (2016), Springer
276. Benazzi F, "Parenteral clonazepam for catatonia", Can J Psychiatry, 36, pp.312~ (1991)
277. Manjunatha N, "Idiopathic recurrent catatonia needs maintenance lorazepam : case report and review", Aust N Z J Psychiatry, 41, pp.625~627 (2007)
278. Grover S, "Long-term maintenance lorazepam for catatonia : a case report", Gen Hosp Psychiatry, 33, pp.82.e1~82.e3 (2011)[DOI]
279. Sienaert P, "A clinical review of the treatment of catatonia", Front Psychiatry, 5, pp.181~ (2014)
280. Lerner AG, "Clonazepam treatment of lysergic acid diethylamide-induced hallucinogen persisting perception disorder with anxiety features", Int Clin Psychopharmacol, 18, pp.101~105 (2003)
281. Thompson C, "A double-blind trial of clonazepam in benign essential tremor", Clin Neuropharmacol, 7, pp.83~88 (1984)
282. Biary N, "Kinetic predominant essential tremor : successful treatment with clonazepam", Neurology, 37, pp.471~474 (1987)
283. Zesiewicz TA, "Evidence-based guideline update : treatment of essential tremor : report of the quality standards subcommittee of the American Academy of Neurology", Neurology, 77, pp.1752~1755 (2011)
284. Alonso-Navarro H, "Current and future neuropharmacological options for the treatment of essential tremor", Curr Neuropharmacol, 18, pp.518~537 (2020)
285. Court JE, "Treatment of tic douloureux with a new anticonvulsant(clonazepam)", J Neurol Neurosurg Psychiatry, 39, pp.297~299 (1976)
286. Brunelli S, "Clonazepam : an old"new"therapy for the treatment of phantom limb pain-a brief report of a retrospective study", Biomed Res Int, 2021, pp.9966059~ (2021)
287. Jääskeläinen SK, "Burning mouth syndrome", Cephalalgia, 37, pp.627~647 (2017)
288. Ganança MM, "Clonazepam in the pharmacological treatment of vertigo and tinnitus", Int Tinnitus J, 8, pp.50~53 (2002)
289. Coccaro EF, "Clinical outcome of psychopharmacologic treatment of borderline and schizotypal personality disordered subjects", J Clin Psychiatry, 59(Suppl 1), pp.30~35 (1998)[DOI]
290. Sadock BJ, "Kaplan & Sadock’s comprehensive textbook of psychiatry" (2000), Lippincott Williams & Wilkins Publishers
291. Gunderson JG, "Borderline personality disorder: a clinical guide. 2nd ed", American Psychiatric Publishing, ~ (2008)
292. Blais MA, "Massachusetts general hospital comprehensive clinical psychiatry", pp.433~444 (2016), Elsevier
293. Markota M, "Benzodiazepine use in older adults: dangers, management, and alternative therapies", Mayo Clin Proc, 91, pp.1632~1639 (2016)
294. Olfson M, "Benzodiazepine use in the United States", JAMA Psychiatry, 72, pp.136~142 (2015)
295. "Clonazepam - Drug summary"[URL]
296. By the American Geriatrics Society 2015 Beers Criteria Update Expert Panel, "American Geriatrics Society 2015 updated beers criteria for potentially inappropriate medication use in older adults", J Am Geriatr Soc, 63, pp.2227~2246 (2015)
297. Conn DK, "Canadian guidelines on benzodiazepine receptor agonist use disorder among older adults title", Can Geriatr J, 23, pp.116~122 (2020)
298. Pollock BG, "Kaplan’s and Sadock’s comprehensive textbook of psychiatry", pp.10475~10487 (2017), Wolters Kluwer
299. Jobert A, "Benzodiazepine withdrawal in older people : what is the prevalence, what are the signs, and which patients?", Eur J Clin Pharmacol, 77, pp.171~177 (2021)
300. Rodriquez CN, "Kaplan’s and Sadock’s comprehensive textbook of psychiatry", pp.10319~10336 (2017), Wolters Kluwer
301. Gisbert S, "Prescribing indicators: an OECD initiative with first results from Germany", Proceedings of the 20th Annual Meeting of the German Drug Utilisation Research Group (GAA) (2013), GMS
302. Hwang SH, "Trends in the prescription of benzodiazepines for the elderly in Korea", BMC Psychiatry, 17, pp.303~ (2017)
303. Yeon-Jung Lim, "Potentially Inappropriate Medications by Beers Criteria in Older Outpatients: Prevalence and Risk Factors", Korean Journal of Family Medicine, 37(6), pp.329~333 (2016), 대한가정의학회
304. Calkin PA, "Tolerability of clonazepam in demented and non-demented geropsychiatric patients", Int J Geriatr Psychiatry, 12, pp.745~749 (1997)
305. Foy A, "Benzodiazepine use as a cause of cognitive impairment in elderly hospital inpatients", J Gerontol A Biol Sci Med Sci, 50, pp.M99~M106 (1995)[DOI]
306. Inoue K, "Possible therapeutic effect of clonazepam upon elderly depressive patients", Psychogeriatrics, 7, pp.33~36 (2007)
307. Morishita S, "Clonazepam augmentation of antidepressants : does it distinguish unipolar from bipolar depression?", J Affect Disord, 71, pp.217~220 (2002)
308. Londborg PD, "Short-term cotherapy with clonazepam and fluoxetine: anxiety, sleep disturbance and core symptoms of depression", J Affect Disord, 61, pp.73~79 (2000)
309. Defrancesco M, "Use of benzodiazepines in Alzheimer’s disease : a systematic review of literature", Int J Neuropsychopharmacol, 18, pp.pyv055~ (2015)
310. Cohen LS, "Panic attack-associated placental abruption : a case report", J Clin Psychiatry, 50, pp.266~267 (1989)
311. Wadhwa PD, "The association between prenatal stress and infant birth weight and gestational age at birth : a prospective investigation", Am J Obstet Gynecol, 169, pp.858~865 (1993)
312. Picchietti DL, "Consensus clinical practice guidelines for the diagnosis and treatment of restless legs syndrome", Willis-Ekbom disease during pregnancy and lactation, 2015, pp.22, 64~77
313. Lin AE, "Clonazepam use in pregnancy and the risk of malformations", Birth Defects Res A Clin Mol Teratol, 70, pp.534~536 (2004)
314. Kjaer D, "Use of phenytoin, phenobarbital, or diazepam during pregnancy and risk of congenital abnormalities: a casetime-control study", Pharmacoepidemiol Drug Saf, 16, pp.181~188 (2007)
315. Enato E, "The fetal safety of benzodiazepines : an updated meta-analysis", J Obstet Gynaecol Can, 33, pp.46~48 (2011)
316. Eadie MJ, "Antiepileptic drugs and pregnancy", pp.153~174 (2016), Adis
317. Fisher JB, "Neonatal apnea associated with maternal clonazepam therapy : a case report", Obstet Gynecol, 66(3 Suppl), pp.34S~35S (1985)[DOI]
318. Jain AE, "Psychotropic drugs in pregnancy and lactation", J Psychiatr Pract, 11, pp.177~191 (2005)
319. Weinstock L, "Clonazepam use during pregnancy", Presented at the Annual Meeting of the American Psychiatric Society (1996)
320. Nonacs RM, "Massachusetts general hospital comprehensive clinical psychiatry", pp.343~352 (2016), Elsevier
321. Uguz F, "A new safety scoring system for the use of psychotropic drugs during lactation", Am J Ther, 28, pp.e118~e126 (2021)[DOI]
322. Kelly LE, "Neonatal benzodiazepines exposure during breastfeeding", J Pediatr, 161, pp.448~451 (2012)
323. Kronenfeld N, "Use of psychotropic medications in breastfeeding women", Birth Defects Res, 109, pp.957~997 (2017)
324. Soussan C, "Drug-induced adverse reactions via breastfeeding : a descriptive study in the French Pharmacovigilance Database", Eur J Clin Pharmacol, 70, pp.1361~1366 (2014)
325. "Clonazepam"[URL]
326. Khandelwal A, "Pharmacology in clinical neurosciences", pp.173~256 (2020), Springer
327. Nishimura A, "Benzodiazepine concentrations in the breast milk and plasma of nursing mothers : estimation of relative infant dose", Breastfeed Med, 16, pp.424~431 (2021)
328. Iqbal MM, "Effects of commonly used benzodiazepines on the fetus, the neonate, and the nursing infant", Psychiatr Serv, 53, pp.39~49 (2002)
329. Järvinen A, "Effects of central and peripheral type benzodiazepine ligands on thyrotropin and prolactin secretion", Neuropeptides, 21, pp.183~191 (1992)
330. Torre DL, "Pharmacological causes of hyperprolactinemia", Ther Clin Risk Manag, 3, pp.929~951 (2007)
331. King BH, "Kaplan’s and Sadock’s comprehensive textbook of psychiatry", pp.8908~8974 (2017), Wolters Kluwer
332. Kalachnik JE, "Benzodiazepine behavioral side effects : review and implications for individuals with mental retardation", Am J Ment Retard, 107, pp.376~410 (2002)
333. Kalachnik JE, "Brief report : clonazepam behavioral side effects with an individual with mental retardation", J Autism Dev Disord, 33, pp.349~354 (2003)
334. Connolly SD, "Practice parameter for the assessment and treatment of children and adolescents with anxiety disorders", J Am Acad Child Adolesc Psychiatry, 46, pp.267~283 (2007)
335. Kliegman RM, "Nelson textbook of pediatrics" (2016), Elsevier
336. Wusthoff CJ, "Management of common neurologic symptoms in pediatric palliative care: seizures, agitation, and spasticity", Pediatr Clin North Am, 54, pp.709~733 (2007)
337. Rosenbaum JF, "Attitudes toward benzodiazepines over the years", J Clin Psychiatry, 66(Suppl 2), pp.4~8 (2005)
338. Uzun S, "Side effects of treatment with benzodiazepines", Psychiatr Danub, 22, pp.90~93 (2010)
339. dos Santos FM, "Pharmacokinetic", pharmacodynamic modeling of psychomotor impairment induced by oral clonazepam in healthy volunteers, 2009, pp.31, 566~574
340. Barker MJ, "Persistence of cognitive effects after withdrawal from long-term benzodiazepine use : a meta-analysis", Arch Clin Neuropsychol, 19, pp.437~454 (2004)
341. Stevens JC, "Benzodiazepines in clinical practice : consideration of their long-term use and alternative agents", J Clin Psychiatry, 66(Suppl 2), pp.21~27 (2005)
342. Stewart SA, "The effects of benzodiazepines on cognition", J Clin Psychiatry, 66(Suppl 2), pp.9~13 (2005)
343. Leipzig RM, "Drugs and falls in older people: a systematic review and meta-analysis: II. Cardiac and analgesic drugs", J Am Geriatr Soc, 47, pp.40~50 (1999)
344. Mula M, "Suicidal ideation in epilepsy and levetiracetam therapy", Epilepsy Behav, 11, pp.130~132 (2007)
345. "Prescription drug information: clonazepam"[URL]
346. Binder RL, "Three case reports of behavioral disinhibition with clonazepam", Gen Hosp Psychiatry, 9, pp.151~153 (1987)
347. Reiter S, "Disinhibition and anger outbursts in adolescents treated with clonazepam", J Clin Psychopharmacol, 11, pp.268~ (1991)
348. Gandotra K, "Clonazepam-related paradoxical behavioral disinhibition : an uncommon but grave adverse effect", J Clin Psychopharmacol, 39, pp.281~282 (2019)
349. Mancuso CE, "Paradoxical reactions to benzodiazepines : literature review and treatment options", Pharmacotherapy, 24, pp.1177~1185 (2004)
350. Brandt SA, "A survey of nonmedical use of tranquilizers, stimulants, and pain relievers among college students:patterns of use among users and factors related to abstinence in non-users", Drug Alcohol Depend, 143, pp.272~276 (2014)
351. van der Meyden CH, "Effects of clobazam and clonazepam on saccadic eye movements and other parameters of psychomotor performance", Eur J Clin Pharmacol, 37, pp.365~369 (1989)
352. Schifano F, "Is there a recreational misuse potential for pregabalin? Analysis of anecdotal online reports in comparison with related gabapentin and clonazepam data", Psychother Psychosom, 80, pp.118~122 (2011)
353. "FDA updates black box warning for benzodiazepines"[URL]
354. Heikman P, "New psychoactive substances as part of polydrug abuse within opioid maintenance treatment revealed by comprehensive high-resolution mass spectrometric urine drug screening", Hum Psychopharmacol, 31, pp.44~52 (2016)
355. "European drug report: trends and developments"[URL]
356. Kuehn BM, "FDA warns of adverse events linked to smoking cessation drug and antiepileptics", JAMA, 299, pp.1121~1122 (2008)
357. Kandemir H, "Behavioral disinhibition, suicidal ideation, and self-mutilation related to clonazepam", J Child Adolesc Psychopharmacol, 18, pp.409~ (2008)
358. Moore TJ, "The FDA and new safety warnings", Arch Intern Med, 172, pp.78~80 (2012)
359. Hesdorffer DC, "An update on antiepileptic drugs and suicide : are there definitive answers yet?", Epilepsy Curr, 10, pp.137~145 (2010)
360. Aronson JK., "Meyler’s side effects of drugs", pp.423~425 (2016), Elsevier
361. Harris EC, "Suicide as an outcome for mental disorders. A meta-analysis", Br J Psychiatry, 170, pp.205~228 (1997)
362. Sjö O, "Pharmacokinetics and side-effects of clonazepam and its 7-amino-metabolite in man", Eur J Clin Pharmacol, 8, pp.249~254 (1975)
363. Brandt J, "Benzodiazepines and Z-drugs : an updated review of major adverse outcomes reported on in epidemiologic research", Drugs R D, 17, pp.493~507 (2017)
364. Toth EC, "A cross-sectional national survey assessing self-reported drug intake behavior, contact with the primary sector and drug treatment among service users of Danish drug consumption rooms", Harm Reduct J, 13, pp.27~ (2016)
365. Lader M, "Benzodiazepines revisited--will we ever learn?", Addiction, 106, pp.2086~2109 (2011)
366. da Silva LGR, "Deprescribing clonazepam in primary care older patients : a feasibility study", Int J Clin Pharm, 44, pp.489~498 (2022)
367. Insel TR, "Cure therapeutics and strategic prevention : raising the bar for mental health research", Mol Psychiatry, 11, pp.11~17 (2006)
368. Ismail Z, "Psychiatry", pp.2027~2040 (2015), John Wiley &Sons
369. Recanatini M, "Drug research meets network science : where are we?", J Med Chem, 63, pp.8653~8666 (2020)
370. Dubovsky SL, "Who is teaching psychopharmacology? Who should be teaching psychopharmacology?", Acad Psychiatry, 29, pp.155~161 (2005)
371. Neppe VM, "Tardive dyskinesia revisited-a clinical management priority perspective : a voyage into high dose buspirone part B", J Psychol Clin Psychiatry, 6, pp.00349~ (2016)
372. Gardner DM, "Competent psychopharmacology", Can J Psychiatry, 59, pp.406~411 (2014)

관련 논문AI추천